key: cord-1026607-3ngbh57g authors: Liu, Hong; Zhao, Yang; Xie, An; Kim, Tae-Yun; Terentyeva, Radmila; Liu, Man; Shi, Guangbin; Feng, Feng; Choi, Bum-Rak; Terentyev, Dmitry; Hamilton, Shanna; Dudley, Samuel C. title: Interleukin-1β, Oxidative Stress, and Abnormal Calcium Handling Mediate Diabetic Arrhythmic Risk date: 2021-01-20 journal: JACC Basic Transl Sci DOI: 10.1016/j.jacbts.2020.11.002 sha: ff04dccb0b26928c1dd88f0354e59cec1a47c572 doc_id: 1026607 cord_uid: 3ngbh57g Diabetes mellitus (DM) is associated with increased arrhythmia. Type 2 DM (T2DM) mice showed prolonged QT interval and increased ventricular arrhythmic inducibility, accompanied by elevated cardiac interleukin (IL)-1β, increased mitochondrial reactive oxygen species (mitoROS), and oxidation of the sarcoplasmic reticulum (SR) Ca(2+) release channel (ryanodine receptor 2 [RyR2]). Inhibiting IL-1β and mitoROS reduced RyR2 oxidation and the ventricular arrhythmia in DM. Inhibiting SR Ca2(+) leak by stabilizing the oxidized RyR2 channel reversed the diabetic arrhythmic risk. In conclusion, cardiac IL-1β mediated the DM-associated arrhythmia through mitoROS generation that enhances SR Ca(2+) leak. The mechanistic link between inflammation and arrhythmias provides new therapeutic options. A prolonged QT interval on the surface electrocardiogram is a risk factor for sudden cardiac death (5) . Clinical studies demonstrated a high prevalence of QT prolongation in DM patients (6) . QT prolongation has been associated with sudden cardiac death in type 2 DM (T2DM), suggesting that electrical remodeling in DM may contribute to ventricular arrhythmias and sudden cardiac death (7) (8) (9) . At a cellular level, an increase in the ventricular action potential duration (APD) with a subsequent increase in early afterdepolarizations (EADs) underlies long QT-associated torsades de pointes ventricular arrhythmias (10) . DM is associated with elevated inflammatory cytokines and mitochondrial oxidative stress. A recent publication implicates macrophage activation in the QT prolongation and increased arrhythmic risk in type 1 DM (T1DM) (11) . We investigated how innate immune activation may contribute to arrhythmic risk in the more prevalent T2DM. Table 1 ). Arrhythmia was also examined in conscious mice using telemetry (data not shown). Table 2 ). Taken together, initial electrophysiological studies demonstrated that DM increased risk markers of sudden cardiac death. OF EADs. At the cellular level, cardiac ventricular APD prolongation is known to underlie surface QT interval lengthening and is associated with increased incidence of electrical oscillations before repolarization called EADs (10). EADs are a fundamental mechanism of ventricular arrhythmias and sudden cardiac death (13, 14) . Resting Ca 2þ leak from the SR through the RyR has been implicated in slow repolarization, EADs and arrhythmias (16) . We confirmed that the RyR was hyperactive using spontaneous Ca 2þ sparks as a readout (Figures 4F and 4G) . There was almost no change in I to peak density between these 2 groups ( Figure 4E ). leads to increased resting SR Ca 2þ release (18) (19) (20) (21) . DM significantly enhanced RyR2 oxidation, while RyR2 phosphorylation was not altered (Figures 5A and 5B ). Both mitoTEMPO and IL-1RA reduced the RyR2 oxidation ( Figures 5A and 5B) . RyR2 oxidation destabilizes an interaction with a channel-associated subunit, calstabin, to lead to Ca 2þ leak (22) . Recently, several drugs, such as S107, have been developed to stabilize the RyR-calstabin interaction and reduce resting SR Ca 2þ leak (23) (24) (25) . We treated cardiomyocytes immediately after they were isolated from diabetic hearts with the RyR stabilizer S107 (1.0 mM) for 2 h or injected S107 (30 mg/kg) in DM mice for 1 week. We found that S107 was able to ameliorate the APD prolongation in vitro (411 AE 42 ms in DM vs. 81 AE 42 ms in DM þ S107; p < 0.001) ( (Figures 5C and 5D ). These data indicated that DM-associated APD prolongation and arrhythmia was mediated by SR Ca 2þ leak from oxidized RyR2 channels. In the present study, we found that DM caused More importantly, our study provides a mechanistic linkage between IL-1b-mediated cardiac (20, 43) . In aging hearts, mitoROS induces the redox modification of RyR2 causing aberrant Ca 2þ handling (44) . At the cellular and animal levels, we showed that, in diabetes, the arrhythmic effect of mitoROS was via oxidative modification of RyR2, leading to increased spontaneous SR Ca 2þ leak, as S107 alone, a drug that inhibits RyR2 channel-mediated resting Ca 2þ leak, reversed the diabetic arrhythmic phenotypes, implying that IL-1b and mitoROS acted predominantly on the RyR2 to mediate their effects. Excessive SR Ca 2þ leak through oxidized RyR2 is known to increase free Ca 2þ ion transportation into mitochondria causing mitochondrial Ca 2þ overload, which subsequently results in more mitoROS production (45) . This vicious cycle helps to sustain arrhythmia in DM. It is possible that our findings may have implications for clinical trial results using sodiumglucose cotransporter-2 inhibitors and glucagonlike peptide-1 agonists to treat DM. Trials have found that these newer glucose-lowering drugs significantly reduce the incidence of major cardiovascular events in diabetic patients and that these cardiovascular benefits are unrelated to their glycemic control effects (46, 47) . Both treatments have been found to lower the expression and secretion of proinflammatory cytokines, such as IL-6, IL-1b, tumor necrosis factor-a, and C-reactive protein (48) . This anti-inflammatory effect may contribute to reduced arrhythmic risk and improved outcomes. Consistent with this idea, blocking IL-1b signaling was antiarrhythmic and independent of the serum glucose level in our study. STUDY LIMITATIONS. We examined neither ROS from other sources nor all ion current components of the cardiac action potential. Nevertheless, mito-TEMPO or S107 alone was sufficient to reverse cardiac electrical remodeling nearly to the control level, suggesting that the impacts from other ROS sources or ion currents are trivial. Second, we did not test the effects of S107 on other cardiac channels. Nevertheless, S107 is reported to bind specifically to RyR (49) . Last, our study cannot rule out a potential effect of IL-1a. Nevertheless, a recent investigation on patients with T2DM revealed that the IL-1b concentration is 4 times as high as that of IL-1a (50). Thus, it is reasonable to conclude that IL-1b-mediated inflammation is the main driver in T2DM-associated arrhythmia. Further investigation using a specific IL-1b neutralizing antibody is needed to confirm our findings. DM results in activation of a cardiac innate immune response associated with increased arrhythmic risk. This arrhythmogenic risk could be inhibited by antagonizing IL-1b, mitoROS, or SR Ca 2þ leak. Each of these approaches represents a possible new therapy for inflammation-induced arrhythmic risk. Also, it is possible that our findings of increased cardiac inflammation in diabetes may explain the increased susceptibility of diabetic patients to the cardiac effects of COVID-19. ACKNOWLEDGMENT The authors thank E. Papa for the technical assistance on flow cytometry. Accessed October 9 Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture Sudden cardiac death in patients with diabetes mellitus and chronic heart failure Diabetes mellitus and risk of sudden cardiac death: a systematic review and meta-analysis Prolonged QTc interval and risk of sudden cardiac death in a population of older adults QT interval, cardiovascular risk factors and risk of death in diabetes Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study Heart ratecorrected QT interval is an independent predictor of all-cause and cardiovascular mortality in individuals with type 2 diabetes: the Diabetes Heart Study Prolonged QTc interval and elevated heart rate identify the type 2 diabetic patient at high risk for cardiovascular death. The Bremen Diabetes Study Acquired long QT syndrome and electrophysiology of torsade de pointes Macrophage-dependent IL-1b production induces cardiac arrhythmias in diabetic mice QT prolongation and malignant arrhythmia: how serious a problem? Molecular and genetic basis of sudden cardiac death Mechanisms of sudden cardiac death: oxidants and metabolism Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells Hyperphosphorylation of RyRs underlies triggered activity in transgenic rabbit model of LQT2 syndrome Impaired glycosylation blocks DPP10 cell surface expression and alters the electrophysiology of Ito channel complex Toll-like receptor 4-induced ryanodine receptor 2 oxidation and sarcoplasmic reticulum Ca 2þ leakage promote cardiac contractile dysfunction in sepsis IL-1b inhibition in cardiovascular complications associated to diabetes mellitus Proarrhythmic remodeling of calcium homeostasis in cardiac disease; implications for diabetes and obesity Oxidized CaMKII (Ca 2þ /Calmodulin-Dependent Protein Kinase II) is essential for ventricular arrhythmia in a mouse model of duchenne muscular dystrophy Palmitoyl-carnitine increases RyR2 oxidation and sarcoplasmic reticulum Ca 2þ leak in cardiomyocytes: Role of adenine nucleotide translocase Fixing ryanodine receptor Ca leak -a novel therapeutic strategy for contractile failure in heart and skeletal muscle Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia Interleukin-18 serum level is elevated in type 2 diabetes and latent autoimmune diabetes Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus Elevated serum TNF-a is related to obesity in type 2 diabetes mellitus and is associated with glycemic control and insulin resistance Antiinflammatory therapy in clinical care: the CANTOS Trial and beyond IL-1b augments TNF-a-mediated inflammatory responses from lung epithelial cells Interleukin-1b modulates proinflammatory cytokine production in human epithelial cells Antiinflammatory therapy with canakinumab for atherosclerotic disease Cardiac ion channel regulation in obesity and the metabolic syndrome: relevance to long QT Syndrome and atrial fibrillation Mitochondrial ROS activate interleukin-1b expression in allergic rhinitis Reactive oxygen species at the crossroads of inflammasome and inflammation Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector? Interleukin-1b and mitochondria damage, and the development of diabetic retinopathy Parkin clearance of dysfunctional mitochondria regulates ROS levels and increases survival of human chondrocytes Mitochondrial ROS drive sudden cardiac death and chronic proteome remodeling in heart failure Mitochondrial dysfunction-associated arrhythmogenic substrates in diabetes mellitus Functional Impact of ryanodine receptor oxidation on intracellular calcium regulation in the heart Redox modification of ryanodine receptors by mitochondriaderived reactive oxygen species contributes to aberrant Ca 2þ handling in ageing rabbit hearts Mitochondrial dysfunction as substrate for arrhythmogenic cardiomyopathy: a search for new disease mechanisms Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with metaanalysis of cardiovascular outcome trials and intensive glucose control trials ACC Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways Anti-inflammatory agents in the treatment of diabetes and its vascular complications Remodeling of ryanodine receptor complex causes "leaky" channels: a molecular mechanism for decreased exercise capacity